| 2026/05/29 | 15:07:23 | Announcement for the important resolutions at the 2026 Annual Shareholders’ Meeting on behalf of Medeon’s major subsidiary, PMC | |
| SEQ_NO |
2 |
Date of announcement |
2026/05/29 |
Time of announcement |
15:07:23 |
| Subject |
Announcement for the important resolutions at the 2026 Annual Shareholders’ Meeting on behalf of Medeon’s major subsidiary, PMC |
| Date of events |
2026/05/29
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2026/05/29
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2025 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:None
4.Important resolutions III.Business report and financial statements:
Ratification of 2025 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:None
7.Any other matters that need to be specified:None |
|
| 2026/05/29 | 15:00:56 | Announcement for the important resolutions at the 2026 Medeologix Annual Shareholders’ Meeting, on behalf of the major subsidiary, Medeologix | |
| SEQ_NO |
1 |
Date of announcement |
2026/05/29 |
Time of announcement |
15:00:56 |
| Subject |
Announcement for the important resolutions at the 2026 Medeologix Annual Shareholders’ Meeting, on behalf of the major subsidiary, Medeologix |
| Date of events |
2026/05/29
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2026/05/29
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2025 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:None
4.Important resolutions III.Business report and financial statements:
Ratification of 2025 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:None
7.Any other matters that need to be specified:None |
|
| 2026/05/08 | 17:12:58 | Medeon Biodesign’s Board of Directors approved incremental investment to its subsidiary Medeologix Corporation | |
| SEQ_NO |
3 |
Date of announcement |
2026/05/08 |
Time of announcement |
17:12:58 |
| Subject |
Medeon Biodesign’s Board of Directors approved incremental investment to its subsidiary Medeologix Corporation |
| Date of events |
2026/05/08
|
To which item it meets |
paragraph 20 |
| Statement |
1.Name and nature of the underlying assets (if preferred shares,
the terms and conditions of issuance shall also be indicated,
e.g., dividend yield, etc.):
The new common shares issued by Medeologix Corporation through a cash
capital increase
2.Date of occurrence of the event:2026/05/08~2026/05/08
3.Date of the Board of Directors’ resolution:2026/05/08
4.Other approval date:N/A
5.Volume, unit price, and total monetary amount of the transaction:
Transaction Volume: No more than 6,000,000 common shares
Issued price per share: NTD 27
Total monetary amount: No more than NTD 162,000,000
6.Trading counterparty and its relationship to the Company
(if the trading counterparty is a natural person and
furthermore is not a related party of the Company, the name
of the trading counterparty is not required to be disclosed):
Medeologix Corporation, the subsidiary of Medeon Biodesign
7.Where the trading counterparty is a related party,
announcement shall also be made of the reason for choosing
the related party as trading counterparty and the
identity of the previous owner, its relationship with
the Company and the trading counterparty, and the previous
date and monetary value of transfer:
Reason for choosing the related party as the trading counterparty:
The investee is the subsidiary of Medeon Biodesign
Previous owner, its relationship with the Company and the trading
counterparty, and the previous date and monetary value of transfer: N/A
8.Where an owner of the underlying assets within the past
five years has been an related party of the Company, the
announcement shall also include the date and price of
acquisition and disposal by the related party, and its
relationship to the Company at the time of the transaction:N/A
9.Matters related to the current disposal of creditors’
rights (including types of collaterals of the disposed
creditor’s rights; if creditor’s rights over a related
party, announcement shall be made of the name of the
related party and the book amount of the creditor’s
rights, currently being disposed of, over such related
party:N/A
10.Profit or loss from the disposal (not applicable in
cases of acquisition of securities) (where originally
deferred, the status of recognition shall be listed and
explained):N/A
11.Terms of delivery or payment (including payment period
and monetary value), restrictive covenants in the contract,
and other important terms and conditions:
Terms of delivery or payment: Payment will be made according to the
fund-raising schedule resolved by Medeologix’s board.
12.The manner in which the current transaction was
decided, the reference basis for the decision on price,
and the decision-making unit:
In accordance with Medeon Board of Directors’ resolution dated 2026/5/8
13.Net worth per share of the Company’s underlying securities
acquired or disposed of:NTD 7.29
14.Cumulative no.of shares held (including the current
transaction), their monetary value, shareholding percentage,
and status of any restriction of rights (e.g., pledges),
as of the present moment:
Cumulative number of shares held (including the current transaction):
No more than 67,774,174 shares
Cumulative monetary amount (including the current transaction):
No more than NTD 1,541,000 thousand.
Cumulative shareholding percentage: No more than 97.33%
The status of any restriction of rights (e.g., pledges): None
15.Ratio of securities investment (including the current
transaction) to the total assets and shareholder’s equity
of the parent company on the latest financial statements,
and the operating capital on the latest financial statements,
as of the present moment:
Current ratio of securities investment to the total assets: 101.98%
Current ratio of securities investment to the equity attributable to
owners of the parent: 113.46%
Working capital: NTD 707,232 thousand.
16.Broker and broker’s fee:None
17.Concrete purpose or use of the acquisition or disposal:
Long-term Equity Investment
18.Whether the directors expressed any objection to the current
transaction:None
19.Whether the counterparty of the current transaction
is a related party:Yes
20.Date of ratification by supervisors or approval by
the Audit Committee:2026/05/08
21.Whether the CPA issued an opinion on the unreasonableness
regarding the current transaction:No
22.Name of the CPA firm:Yangtze CPAs and Co.
23.Name of the CPA:Hu, Hsiang-Ning
24.License no.of the CPA:Taichung CPA Association No.191
25.Whether the transaction involved in change of business model:No
26.Details on change of business model: N/A
27.Details on transactions with the counterparty for the past
year and the expected coming year:N/A
28.Source of funds:working capital
29.Date on which material information regarding the same event
has been previously released: NA
30.Any other matters that need to be specified:None |
|
| 2026/05/08 | 16:35:40 | Medeon Board of Directors resolved not to proceed the private placement of common shares approved by the 2025 Annual Shareholders’ Meeting. | |
| SEQ_NO |
2 |
Date of announcement |
2026/05/08 |
Time of announcement |
16:35:40 |
| Subject |
Medeon Board of Directors resolved not to proceed the private placement of common shares approved by the 2025 Annual Shareholders' Meeting. |
| Date of events |
2026/05/08
|
To which item it meets |
paragraph 16 |
| Statement |
1.Date of the board of directors resolution for the change:2026/05/08
2.Effective registration date of the original plan:NA
3.Resolution date of additional issuance:NA
4.Major change Reason for the change:
The Company resolved on June 20, 2025 to proceed with the issuing no more
than 35,000,000 common shares for capital increase through private
placement by the Shareholders’Meeting. The issuing shall be completed
within 1 year from the date of the resolution of the
Shareholders’Meeting, with the maximum number of installments not
exceeding three. Due to the period of the private placement proposal is
going to expire and the qualified strategic investors have not yet been
identified, the Medeon board meeting dated May 8, 2026 has resolved not to
proceed the private placement of common shares for rest of the period.
5.Content of each and every successive previously changed
plan for raising of funds before and after change:NA
6.Projected timetable for execution:NA
7.Projected completion date:NA
8.Projected possible benefits:NA
9.Difference from original projected benefits:NA
10.Effect of the current change on shareholder equity:NA
11.Abstract of the original lead underwriter’s appraisal opinion:NA
12.Any other matters that need to be specified:None |
|
| 2026/05/08 | 16:27:11 | Medeon Board of Directors approved the 2026Q1 consolidated financial reports | |
| SEQ_NO |
1 |
Date of announcement |
2026/05/08 |
Time of announcement |
16:27:11 |
| Subject |
Medeon Board of Directors approved the 2026Q1 consolidated financial reports |
| Date of events |
2026/05/08
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of the board of directors submitted or approved:2026/05/08
2.Date of the audit committee approved:2026/05/08
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2026/01/01~2026/03/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):114,288
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):17,402
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(131,360)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(135,120)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(135,099)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(121,858)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(1.26)
11.Total assets end of the period (thousand NTD):1,679,425
12.Total liabilities end of the period
(thousand NTD):271,076
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,358,175
14.Any other matters that need to be specified:None |
|
| 2026/05/07 | 15:41:07 | Medeon, on behalf of its subsidiary Medeologix Corporation, announces the resolution of BOD on the issuance of common shares. | |
| SEQ_NO |
2 |
Date of announcement |
2026/05/07 |
Time of announcement |
15:41:07 |
| Subject |
Medeon, on behalf of its subsidiary Medeologix Corporation, announces the resolution of BOD on the issuance of common shares. |
| Date of events |
2026/05/07
|
To which item it meets |
paragraph 11 |
| Statement |
1.Date of the board of directors resolution:2026/05/07
2.Source of capital increase funds:
Issuance of common shares through a cash capital increase
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance?GNT$162,000,000
Number of shares issued?G6,000,000 Common Shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:NA
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:NA
7.Par value per share:NT$10
8.Issue price: NT$27
9.Number of shares subscribed for by or allocated to employees:
10% of the total issued shares, amounting to 600,000 shares, are reserved
for subscription by the Medeologix Corporation’s employees.
10.Number of shares publicly sold:NA
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
The remaining number of shares to be issued will be subscribed in
proportion to the shareholders and their shareholdings as recorded in
the shareholders’ register on the basis of the subscription date.
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
Any shares forfeited by existing shareholders or employees, and any
fractional shares resulting from insufficient aggregation, shall be
subscribed by specific persons designated by the Chairman at the issue
price.
13.Rights and obligations of these newly issued shares:
The rights and obligations of the new shares issued in this cash capital
increase are identical to those of the originally issued common shares.
14.Utilization of the funds from the capital increase:
For the purpose of increasing working capital.
15.Any other matters that need to be specified:None |
|
| 2026/05/07 | 15:26:16 | Announcement of a statutory merger between Medeologix Corporation’s wholly owned subsidiaries Medeologix LLC and Medeologix, Inc. | |
| SEQ_NO |
1 |
Date of announcement |
2026/05/07 |
Time of announcement |
15:26:16 |
| Subject |
Announcement of a statutory merger between Medeologix Corporation’s wholly owned subsidiaries Medeologix LLC and Medeologix, Inc. |
| Date of events |
2026/05/07
|
To which item it meets |
paragraph 11 |
| Statement |
1.Type of merger and acquisition (e.g.merger, spin-off , acquisition,
or share transfer):Merger
2.Date of occurrence of the event:2026/05/07
3.Names of companies participating in the merger and acquisition
(e.g., name of the other company participating in
the merger, newly established company in a spin-off,
acquired company, or company whose shares are transferred):
Surviving company: Medeologix LLC
Dissolved company: Medeologix, Inc.
4.Trading counterparty (e.g., name of the other company
participating in the merger, company spinning off, or trading
counterparty to the acquisition or share transfer):
Same as above.
5.Whether the counterparty of the current transaction is a
related party:Yes
6.Relationship between the trading counterparty and the Company
(investee company in which the Company has re-invested and has
shareholding of XX%), explanation of the reasons for the
decision to acquire from or transfer shares to an affiliated
enterprise or related party, and whether it will affect
shareholders’ equity:
Both the surviving company, Medeologix LLC, and the dissolved company,
Medeologix, Inc., are wholly owned subsidiaries of Medeologix Corporation.
The merger will not affect the rights and interests of the Company’s
shareholders.
7.Purpose and conditions of the merger and acquisition, including
the reason, consideration conditions and payment schedule of the
merger and acquisition:
The merger is intended to consolidate the resources of the Group, and will
be implemented through a statutory merger in accordance with the laws of
California.
8.Anticipated benefits of the merger and acquisition:
The merger is expected to enhance operational efficiency and reduce
management costs.
9.Effect of the merger and acquisition on net worth per share
and earnings per share:None.
10.Types of consideration for mergers and acquisitions and sources
of funds:N/A
11.Share exchange ratio and calculation assumptions:N/A
12.Whether the CPA, lawyer or securities underwriter issued an
opinion on the unreasonableness regarding the transaction:N/A
13.Name of accounting, law or securities firm:N/A
14.Name of CPA or lawyer:N/A
15.Number of CPA or lawyer license:N/A
16.The content of the independent expert opinion on the
reasonableness of the share exchange ratio, cash or other
assets allotted to shareholders in this merger and acquisition
(1.The method, principles, or calculations adopted for
determination of the public tender offer price, and comparison
with the market-value method, cost method, and discounted cash
flow method commonly used internationally; 2.comparison of the
financial condition, profit status, and price-to-earnings
ratio of the subject company with those of TWSE or TPEx listed
companies in the same industry; 3.if a price appraisal report
of an appraisal organization is taken into account in the public
tender offer price, the opinion shall specify the content and
conclusion of the appraisal report; and 4.if assets or shares
of the subject company, or of the surviving company in the
case of a merger, are listed as collateral in the tender
offeror’s financing repayment plan, the opinion shall disclose
the collateralization terms, and assessment of the impact on
the financial and operational soundness, of the subject company
or of the surviving company of the merger.):N/A
17.Estimated date of completion:
The tentative merger record date is May 26, 2026.
18.Matters related to the assumption of corporate rights and
obligations of the dissolving company (or spin-off) by the
existing or newly-established company:
Upon completion of the merger, the Surviving company, Medeologix LLC,
will acquire all assets, rights, and liabilities of the Dissolved company,
Medeologix, Inc.
19.Basic information of companies participating in the merger:
Surviving company: Medeologix LLC , principally engaged in the manufacture
and sale of medical devices.
Dissolved company: Medeologix, Inc. , principally engaged in the
manufacture and sale of medical devices.
20.Matters related to the spin-off (including estimated value
of the business and assets planned to be transferred to the
existing company or new company.The total no.of shares to
be acquired by the spun-off company or its shareholders, and
their respective types and no.Matters related to the reduction,
if any, in capital of the spun-off company) (note: not applicable
for announcements unrelated to spin-offs):N/A
21.Conditions and restrictions for future transfer of shares
resulting from the merger and acquisition:N/A
22.Post-merger and acquisition plan: (1) Willingness to continue
operating the business of the company, and the contents of
plans to that effect (2) Dissolution; delisting from an exchange
(or OTC market); material changes in organization, capital,
business plan, financial operations and production; accommodation
or utilization of staff and assets critical to the Company; or
any other matter of material significance that would affect the
company’s shareholder equity:None
23.Other important terms and conditions:None
24.Other major matters related to the mergers and acquisitions:None
25.Any objections from directors to the transaction:None
26.Information on interested directors involved in the mergers
and acquisitions (name of natural person director or name of
legal person director and its representative, material
interest of the director or the legal person represented by
the director (including but not limited to form of actual
or expected investment in another company in the merger,
shareholding, transaction price, participation in the subject
company’s business or otherwise, and other terms of
investment), reason for recusal or otherwise, details of
recusal, and reason for a resolution for or against the merger
proposal):None
27.Is it related to new business model ?:No
28.Explanation of new business model:N/A
29.Transactions with the counterparty for the past one year
and the next year:N/A
30.Source of funds:N/A
31.Any other matters that need to be specified:
The merger record date is tentatively set as May 26, 2026, and the
Chairman is authorized to adjust the actual merger record date in
accordance with applicable regulations and operational needs. |
|
| 2026/04/30 | 17:38:49 | Announcement of the Board of Directors Meeting Date for Approval of the First-Quarter 2026 Financial Report | |
| SEQ_NO |
1 |
Date of announcement |
2026/04/30 |
Time of announcement |
17:38:49 |
| Subject |
Announcement of the Board of Directors Meeting Date for Approval of the First-Quarter 2026 Financial Report |
| Date of events |
2026/04/30
|
To which item it meets |
paragraph 31 |
| Statement |
1.Date of a notice of the board of directors meeting is issued:2026/04/30
2.Expected date of the board of directors meeting is convened:2026/05/08
3.Expected year and quarter of the financial reports
or the annual self-assessed financial information
submitted to the board of directors or approved by
the board of directors: First-Quarter 2026
4.Any other matters that need to be specified:None |
|
| 2026/03/23 | 14:35:29 | The Company has been required by TPEx to announce the financial data according to the regulations. | |
| SEQ_NO |
1 |
Date of announcement |
2026/03/23 |
Time of announcement |
14:35:29 |
| Subject |
The Company has been required by TPEx to announce the financial data according to the regulations. |
| Date of events |
2026/03/23
|
To which item it meets |
paragraph 53 |
| Statement |
1.Date of occurrence of the event: 2026/03/23
2.Cause of occurrence:Announced as required by the TPEx
3.Financial and business information:
Unit: (NT$million)
(1) Monthly
Feb 2026 Feb 2025 YoY Change %
————————————————————————–
Sales revenue 47.9 36.2 32.3% (Revenue increased)
Loss before income tax (39.4) (63.8) 38.2% (Losses reduced)
Net Loss attributable to
Owners of the parent (35.5) (59.4) 40.2% (Losses reduced)
EPS (NT$) (0.4) (0.6) 43.1% (Losses reduced)
==========================================================================
(2)Quarterly
Q4 2025 Q4 2024 YoY Change %
————————————————————————–
Sales revenue 114.9 77.3 48.5% (Revenue increased)
Loss before income tax (154.7) (225.9) 31.5% (Losses reduced)
Net Loss attributable to
Owners of the parent (137.1) (208.8) 34.3% (Losses reduced)
EPS (NT$) (1.5) (2.3) 34.5% (Losses reduced)
==========================================================================
(3)Cumulative for the last four seasons
Latest 4 quarters accumulation
(Q1 2025 to Q4 2025)
————————————————————————–
Revenue 419.4
Loss before income tax (719.7)
Net Loss attributable to
Owners of the parent (668.1)
EPS (NT$) (7.2)
==========================================================================
4.Any material information that needs to be specified
according to Article 4 of Taipei Exchange Procedures
for Verification and Disclosure of Material Information
of Companies with TPEx Listed Securities:
Medeon has disclosed material information titled ‘Urocross Expander
System Officially Obtained U.S. FDA 510(k) Clearance’ in accordance
with Article 53 over the past six business days.
5.Any material information in a press conference listed
under Article 11 of Taipei Exchange Procedures for
Verification and Disclosure of Material Information of
Companies with TPEx Listed Securities:
Medeon has not held any press conferences to explain material information
in the past six business days.
6.Any other matters that need to be specified:
(1)The aforementioned financial information for February 2026 and its YOY
comparison consists in the consolidated reviewed amounts prepared by
the Company adopting the IFRS, and has not been audited (reviewed) by
CPA. This information is provided for investors’ reference only.
(2)The information for the latest quarter (Q4 2025) refers to single
quarter amounts, not cumulative amounts from the latest financial
reports, and are consolidated amounts prepared under the IFRS, which
have been audited (reviewed) by CPA. This information is provided for
investors’ reference only.
(3)The information accumulated over the last 4 quarters consists in the
consolidated amounts from Q1 2025 to Q4 2025 prepared by the Company
adopting the IFRS, and has been audited (reviewed) by CPA. This
information is provided for investors’ reference only. |
|
| 2026/03/13 | 16:44:17 | Urocross Expander System Officially Obtained U.S. FDA 510(k) Clearance | |
| SEQ_NO |
1 |
Date of announcement |
2026/03/13 |
Time of announcement |
16:44:17 |
| Subject |
Urocross Expander System Officially Obtained U.S. FDA 510(k) Clearance |
| Date of events |
2026/03/13
|
To which item it meets |
paragraph 10 |
| Statement |
1.Date of occurrence of the event:2026/03/13
2.New drug name or code:Urocross Expander System
3.Indication:
The Urocross Expander System is a retrievable, non-permanent implant
system developed to improve lower urinary tract symptoms (LUTS)
associated with Benign Prostatic Hyperplasia (BPH). The system gently
expands the prostatic urethral tissue through a minimally invasive
procedure performed under mild anesthesia, thereby relieving obstruction
and improving urinary flow.
4.Planned development stages:
The Urocross Expander System has officially obtained the 510(k) Clearance
from the U.S. FDA on 2026/03/13 (Taipei Time).
5.Current development stage:
(1) Submission of application / approval granted / approval not granted /
results of each phase of clinical trials (including interim analysis)
/ occurrence of other material events affecting new drug development:
The Urocross Expander System has officially obtained the U.S. FDA for
510(k) Clearance
(2) In the event that approval is not granted by the competent authority
for the intended use, or the results of any phase of clinical trials
(including interim analysis) fail to reach statistical significance,
or other material events occur that may affect new drug development,
the risks faced by the Company and corresponding countermeasures:
Not Applicable
(3) In the event that approval has been granted by the competent authority
for the intended use, or the results of any phase of clinical trials
(including interim analysis) reach statistical significance, or other
material events occur that may affect new drug development, the
Company’s future business plans and directions:
Not Applicable
(4) Cumulative research and development expenses incurred?G
Due to the involvement of information pertaining to future
international licensing negotiations, and to avoid impacting the deal
amount while safeguarding the rights and interests of investors, the
details will not be disclosed at this time.
6.Upcoming development plan:
Subsequent efforts will continue to advance preparations for product
launch while simultaneously conducting international strategic
collaboration discussions.
7.Market situation:
The probability of men suffering from BPH increases with age. The
estimated population in only the United States with BPH is reaching 40
million. As the population continues to age, the number of BPH patients
is expected to grow accordingly. According to a market research report by
Grand View Research, the global market for medical devices treating BPH
reached USD 1.67 billion in 2024. It is projected that from 2025 to 2033,
the BPH-related market will grow at a compound annual growth rate (CAGR)
of 9.4%, reaching USD 3.71 billion in 2033.
8.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 8
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
The Company has successfully obtained 510(k) clearance, enabling it to
legally commence sales activities in the U.S. market. Commercialization
plans and mass production initiatives will be rolled out in phases.
Concurrently, the Company has initiated market entry plans for Taiwan,
including applying for Taiwanese regulatory approval and progressively
establishing sales channels. Market entry efforts will be dynamically
adjusted in alignment with global licensing negotiations and overall
strategic priorities, with the core objective of maximizing the project’s
overall value.
9.New drug development requires long process, vast investments and with
no guarantee in success which may pose investment risks.The investors
are advised to exercise caution and conduct thorough evaluation.: |
|
